We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
-7.23%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$5.58B
AUM Growth
-$2.21B
Cap. Flow
-$1.68B
Cap. Flow %
-30.12%
Top 10 Hldgs %
58.92%
Holding
80
New
11
Increased
25
Reduced
9
Closed
15

Top Buys

Rank Stock Value
1
FTAI icon
FTAI Aviation
FTAI
+$313M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$153M
3
VST icon
Vistra
VST
+$141M
4
NFE icon
New Fortress Energy
NFE
+$115M
5
MCY icon
Mercury Insurance
MCY
+$98.2M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$251M
2
UAL icon
United Airlines
UAL
+$96.7M
3
FLR icon
Fluor
FLR
+$65.3M
4
DAL icon
Delta Air Lines
DAL
+$49M
5
PARA
Paramount Global Class B
PARA
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 37.06%
2 Utilities 27.45%
3 Energy 10.46%
4 Financials 7.97%
5 Technology 6.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLN
1
Talen Energy Corp
TLN
$16.7B
$1.22B 21.91%
6,123,500
– –
TEVA icon
2
Teva Pharmaceuticals
TEVA
$41.2B
$393M 7.04%
25,550,000
+8,550,000
+50% +$153M
GLNG icon
3
Golar LNG
GLNG
$5.13B
$341M 6.11%
8,975,149
+1,264,938
+16% +$49.6M
FTAI icon
4
FTAI Aviation
FTAI
$22.2B
$294M 5.26%
+2,645,000
New +$313M
QDEL icon
5
QuidelOrtho
QDEL
$838M
$215M 3.85%
6,140,000
+590,000
+11% +$24.1M
NFE icon
6
New Fortress Energy
NFE
$101M
$202M 3.62%
24,338,675
+9,338,675
+62% +$115M
ROIV icon
7
Roivant Sciences
ROIV
$26.2B
$179M 3.21%
17,767,076
-2,232,924
-11% -$24.1M
ARQT icon
8
Arcutis Biotherapeutics
ARQT
$3.18B
$172M 3.07%
10,966,672
– –
BGC icon
9
BGC Group
BGC
$4.89B
$158M 2.83%
17,226,380
+250,000
+1% +$2.34M
TAC icon
10
TransAlta
TAC
$3.93B
$112M 2.01%
12,000,000
+4,387,337
+58% +$48.6M
VST icon
11
Vistra
VST
$47.4B
$111M 1.99%
+945,969
New +$141M
COOP
12
DELISTED
Mr. Cooper
COOP
$110M 1.98%
921,537
-146,143
-14% -$15.3M
ALIT icon
13
Alight
ALIT
$407M
$105M 1.88%
886,041
+303,707
+52% +$40M
IART icon
14
Integra LifeSciences
IART
$1.34B
$102M 1.83%
4,643,672
+2,025,331
+77% +$47.6M
MCY icon
15
Mercury Insurance
MCY
$6.07B
$102M 1.83%
+1,821,783
New +$98.2M
ADPT icon
16
Adaptive Biotechnologies
ADPT
$3.97B
$97.5M 1.75%
13,117,851
-1,482,149
-10% -$11.4M
SDGR icon
17
Schrodinger
SDGR
$1.36B
$94.8M 1.7%
4,800,000
-200,000
-4% -$4.5M
AMRX icon
18
Amneal Pharmaceuticals
AMRX
$5.79B
$90M 1.61%
10,735,977
+14,199
+0.1% +$119K
COLL icon
19
Collegium Pharmaceutical
COLL
$956M
$89.5M 1.6%
3,000,000
+650,000
+28% +$19.9M
RNW icon
20
ReNew
RNW
$2.25B
$85.6M 1.53%
14,527,412
– –
OPK icon
21
Opko Health
OPK
$1.02B
$80.9M 1.45%
48,706,640
– –
KNSA icon
22
Kiniksa Pharmaceuticals
KNSA
$5.93B
$75.1M 1.35%
3,383,239
+764,136
+29% +$15.7M
FLG
23
Flagstar Bank National Association
FLG
$5.82B
$74.7M 1.34%
+6,425,000
New +$72.3M
LBTYA icon
24
Liberty Global Class A
LBTYA
$3.6B
$69.1M 1.24%
6,002,651
-592,788
-9% -$6.9M
SSYS icon
25
Stratasys
SSYS
$774M
$64.6M 1.16%
6,597,333
+406,333
+7% +$4.18M
1
2 3 4

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

Rubric Capital Management (New York)'s Q1 2025 Portfolio in Review

As of Q1 2025, Rubric Capital Management (New York) held 80 positions worth $5.58B, down 28% from $7.79B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Rubric Capital Management (New York) withdrew a net $1.68B in Q1 2025, closing 15 positions and reducing 9 holdings. Its most notable exit was Viatris, an estimated $251M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 28% a quarter earlier, followed by Utilities and Energy.

Against the trend, Rubric Capital Management (New York) opened a new position in FTAI Aviation worth $294M.

  • Rubric Capital Management (New York)'s largest Q1 2025 buy was FTAI Aviation: 2,645,000 shares worth $294M.
  • Rubric Capital Management (New York) added most to Teva Pharmaceuticals in Q1 2025, an estimated $153M increase.
  • Rubric Capital Management (New York)'s biggest Q1 2025 reduction was Roivant Sciences, cutting an estimated $24.1M.
  • Rubric Capital Management (New York) fully exited Viatris in Q1 2025, selling an estimated $251M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 59% of its $5.58B portfolio in Q1 2025.
  • Rubric Capital Management (New York) opened 11 new positions and closed 15 in Q1 2025.
  • Rubric Capital Management (New York)'s portfolio value fell 28% quarter-over-quarter to $5.58B.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2025, filed 14 May 2025.